Literature DB >> 18171285

Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops.

Martin Enders1, Andrea Weidner, Tessa Rosenthal, Carola Baisch, Lea Hedman, Maria Söderlund-Venermo, Klaus Hedman.   

Abstract

BACKGROUND: In the diagnosis of parvovirus B19 infection, the detection of virus-specific IgG in the absence of virus-specific IgM is considered to indicate past immunity.
METHODS: We determined the diagnostic value of a high-quality B19 IgM EIA, compared with that of a VP1 IgG avidity EIA, a VP2 IgG epitope-type specificity (ETS) EIA, and real-time polymerase chain reaction (PCR) in the diagnosis of maternal B19 infection during nonimmune fetal hydrops.
RESULTS: Serum samples from 101 pregnant women with confirmed B19-induced fetal hydrops were collected at the time of invasive prenatal diagnosis. The samples were investigated for B19 IgM, VP1 IgG avidity, and VP2 IgG ETS. With the B19 IgM EIA, 78 women (77.2 %) showed positive results, 15 (14.9%) showed negative results, and 8 (7.9 %) showed equivocal results. According to the combined B19 IgG avidity and IgG ETS EIA results, only 5 (5%) of 101 women were classified as having past immunity. Available serum samples (n = 24) that had nondiagnostic results in the antibody assays were further investigated by PCR. All were B19 DNA positive (mean load, 2.5 x 10(4) genome equivalents/mL; range, 2.5 x 10(3) - 7.8 x 10(6)).
CONCLUSIONS: At the time of B19-induced hydrops, detection of B19 DNA in maternal blood had the best diagnostic sensitivity for identifying maternal B19 infection. However, given the long persistence of B19 DNAemia, supplementary measurement of VP1 IgG avidity and VP2 IgG ETS improves the precision of diagnosis and management of pregnant women affected by the B19 virus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171285     DOI: 10.1086/524302

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

2.  Parvovirus infection mimicking systemic lupus erythematosus.

Authors:  Mohan Cooray; Joshua J Manolakos; Douglas S Wright; Shariq Haider; Ameen Patel
Journal:  CMAJ       Date:  2013-08-26       Impact factor: 8.262

Review 3.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 4.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

5.  The seroprevalence of parvovirus B19 infection in pregnant women in Sudan.

Authors:  O Adam; T Makkawi; U Reber; H Kirberg; A M Eis-Hübinger
Journal:  Epidemiol Infect       Date:  2014-03-20       Impact factor: 4.434

6.  Congenital Parvovirus B19 Infection: Persistent Viremia and Red Blood Cell Aplasia.

Authors:  Sruti S Nadimpalli; Russell S Miller; Vasudeva M Kamath; Christiana R Farkouh; Chia-Ling Nhan-Chang; Jennifer A Rathe; Amélie Collins; Jennifer M Duchon; Natalie Neu; Lynn L Simpson; Adam J Ratner
Journal:  Open Forum Infect Dis       Date:  2015-04-15       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.